Patents by Inventor Ryan E. Holcomb
Ryan E. Holcomb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240091302Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more free/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.Type: ApplicationFiled: November 16, 2023Publication date: March 21, 2024Applicant: ACADIA PHARMACEUTICALS, INC..Inventors: Christopher Bryant, Mark Manning, Ryan E. Holcomb
-
Patent number: 11844764Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.Type: GrantFiled: March 2, 2022Date of Patent: December 19, 2023Assignee: ACADIA PHARMACEUTICALS, INC.Inventors: Christopher Bryant, Mark C. Manning, Ryan E. Holcomb
-
Publication number: 20230201300Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Prader-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.Type: ApplicationFiled: February 21, 2023Publication date: June 29, 2023Applicant: LEVO THERAPEUTICS, INC.Inventors: Mark C. Manning, Ryan E. Holcomb, Derrick S. Katayama, Christopher Bryant
-
Publication number: 20230014640Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.Type: ApplicationFiled: March 2, 2022Publication date: January 19, 2023Applicant: LEVO THERAPEUTICS, INC.Inventors: Christopher Bryant, Mark C. Manning, Ryan E. Holcomb
-
Patent number: 11298399Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Prader-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.Type: GrantFiled: November 18, 2021Date of Patent: April 12, 2022Assignee: LEVO THERAPEUTICS, INC.Inventors: Christopher Bryant, Mark C. Manning, Ryan E. Holcomb
-
Publication number: 20220072086Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.Type: ApplicationFiled: November 18, 2021Publication date: March 10, 2022Applicant: LEVO THERAPEUTICS, INC.Inventors: Christopher Bryant, Mark C. Manning, Ryan E. Holcomb
-
Patent number: 11207373Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.Type: GrantFiled: September 20, 2019Date of Patent: December 28, 2021Assignee: LEVO THERAPEUTICS, INC.Inventors: Christopher Bryant, Mark C. Manning, Ryan E. Holcomb
-
Patent number: 10967040Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.Type: GrantFiled: July 24, 2020Date of Patent: April 6, 2021Assignee: Levo Therapeutics, Inc.Inventors: Mark C. Manning, Ryan E. Holcomb, Derrick S. Katayama, Christopher Bryant, Sara Cotter, Joseph William Cormier
-
Publication number: 20200353029Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.Type: ApplicationFiled: July 24, 2020Publication date: November 12, 2020Applicant: Levo Therapeutics, Inc.Inventors: Mark C. Manning, Ryan E. Holcomb, Derrick S. Katayama, Christopher Bryant, Sara Cotter, Joseph William Cormier
-
Publication number: 20200093885Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.Type: ApplicationFiled: September 20, 2019Publication date: March 26, 2020Inventors: Christopher BRYANT, Mark C. Manning, Ryan E. Holcomb
-
Publication number: 20200093884Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.Type: ApplicationFiled: September 20, 2019Publication date: March 26, 2020Inventors: Mark C. MANNING, Ryan E. Holcomb, Derrick S. Katayama, Christopher Bryant
-
Patent number: 10024797Abstract: Herein disclosed are biosensing systems that measure lactose concentration in a solution.Type: GrantFiled: November 22, 2011Date of Patent: July 17, 2018Assignee: Colorado State University Research FoundationInventors: Kenneth F. Reardon, David S. Dandy, Ryan E. Holcomb
-
Publication number: 20130244266Abstract: Herein disclosed are biosensing systems that measure lactose concentration in a solution.Type: ApplicationFiled: November 22, 2011Publication date: September 19, 2013Inventors: Kenneth F. Reardon, David S. Dandy, Ryan E. Holcomb